Rallybio Corporation (RLYB)
| Bid | 0.3 |
| Market Cap | 13M |
| Revenue (ttm) | 636K |
| Net Income (ttm) | -57.77M |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -0.23 |
| Forward PE | -0.34 |
| Analyst | Hold |
| Ask | 0.33 |
| Volume | 29,641 |
| Avg. Volume (20D) | 107,285 |
| Open | 0.33 |
| Previous Close | 0.32 |
| Day's Range | 0.31 - 0.33 |
| 52-Week Range | 0.22 - 2.00 |
| Beta | -1.35 |
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclona...
Analyst Forecast
According to 4 analyst ratings, the average rating for RLYB stock is "Hold." The 12-month stock price forecast is $15, which is an increase of 4701.54% from the latest price.
Stock Forecasts
3 weeks ago · businesswire.com
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAITNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
2 months ago · businesswire.com
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...